Clinical Trial Update: A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A [Phase 2]

View source ↗

Summary

Phase 2 study of the recombinant AAV2/6 factor VIII gene therapy SB-525 (PF-07055480) for severe hemophilia A has completed, with results posted on 2025-09-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• SB-525 (PF-07055480)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 2 | Status: COMPLETED | Results posted: 2025-09-30